Physician profile
Mark Pass
NPI 1437156288
$1,060.55
in general payments reported to CMS, 2019-2025
16 companies · $128 in 2025
The $128 reported for 2025 was more than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2021: $85.00 · 2022: $37.95 · 2023: $247 · 2024: $129 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $148.30 | 2019 | |
| Astellas Pharma US INC | $140.00 | 2019-2021 | |
| Axsome Therapeutics, INC. | $124.05 | 2023 | Sunosi |
| Lilly USA, LLC | $110.59 | 2025 | Kisunla |
| Otsuka America Pharmaceutical, INC. | $108.76 | 2023 | Rexulti |
| Verrica Pharmaceuticals INC. | $98.41 | 2024 | Ycanth |
| Boston Scientific Corporation | $64.41 | 2019 | |
| Janssen Pharmaceuticals, INC | $55.93 | 2019 | |
| Glaxosmithkline, LLC. | $53.51 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Paratek Pharmaceuticals, INC. | $47.82 | 2024-2025 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $35.36 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.40 | 2022 | |
| Acadia Pharmaceuticals INC | $14.55 | 2022 | |
| Bardy Diagnostics, INC. | $13.28 | 2019 | |
| Allergan, INC. | $11.17 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.